Latest Articles

Publication Date
Analysis of Drug Clinical Trials in Obstetrics and Gynecology: A Five-Year Retrospective Study from a Public Tertiary Specialty Hospital in China.

Women remain underrepresented in clinical drug development despite their unique biological characteristics and growing disease burden. In China, this disparity is particularly concerning given the rising incidence of gynecologic conditions …

Published: June 30, 2026, midnight
The Follicular Immune Checkpoint: PD-1/PD-L1 and Immune Tolerance in Oocyte Competence and IVF Failure.

Oocyte formation occurs successfully within a meticulously controlled follicular environment characterized by well-documented endocrine, metabolic, and paracrine signals. Yet, the immunological landscape of the follicle and its role in influencing …

Published: June 24, 2026, midnight
sMICA/sMICB and Immune Checkpoint in Endometriosis: Toward a Minimally Invasive Diagnostic Model Based on Machine Learning.

Background: Endometriosis is a complex condition that impairs women's quality of life and reproductive potential. Its diagnosis remains significant challenge for clinicians. The aim of the study was to investigate …

Published: March 12, 2026, midnight
Identification of a circulating immunological signature as a liquid biopsy approach for the diagnosis of endometriosis.

Endometriosis is a chronic inflammatory disease characterized by ectopic endometrial tissue growth, causing pain and infertility. Diagnosis is often delayed due to reliance on imaging and invasive methods, highlighting the …

Published: Jan. 23, 2026, midnight
The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective.

Ovarian clear cell carcinoma (OCCC) is a rare, aggressive epithelial ovarian cancer subtype, accounting for approximately 10% of cases and associated with a poor prognosis due to chemoresistance and unique …

Published: Nov. 26, 2025, midnight
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - BioMed Central

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis BioMed Central

Published: Feb. 28, 2025, 10:47 a.m.
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis - bmcwomenshealth.biomedcentral.com

Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis bmcwomenshealth.biomedcentral.com

Published: Feb. 28, 2025, 10:47 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!